---
title: "How should anti-CD20 monoclonal antibodies be utilized in CLL?"
image: "https:\/\/i.ytimg.com\/vi\/zwSpqEIcYXM\/hqdefault.jpg"
vid_id: "zwSpqEIcYXM"
categories: "Education"
tags: ["Imedex","CME","Continuing Medical Education"]
date: "2021-11-26T08:36:27+03:00"
vid_date: "2015-05-07T15:17:02Z"
duration: "PT24M11S"
viewcount: "638"
likeCount: "4"
dislikeCount: "0"
channel: "ImedexCME"
---
{% raw %}Filmed on location in Barcelona, Spain during the 11th European Congress on Hematologic Malignancies, this webcast is part of a series that provides cutting-edge updates and expert perspectives on the diagnosis and management of hematologic malignancies, including multiple myeloma, chronic lymphocytic leukemia, and Hodgkin's and non-Hodgkin's lymphomas. By combining stimulating didactic sessions, interactive panel discussions, and lively debates by internationally renowned specialists, presentations from this Congress supply healthcare professionals with the information they need to optimize care and outcomes for their patients with hematologic malignancies.<br /><br />In this presentation, Dr. Emili Montserrat examines whether current data supports the utilization of anti-CD20 monoclonal antibodies in Chronic Lymphocytic Leukemia (CLL).<br /><br />Â© 2015 Imedex, LLC.{% endraw %}
